Yatharth Hospital Revenue Rises 51% to ₹3,927 Million in Q1

Yatharth Hospital & Trauma Care Services Ltd. reported Q1 FY27 consolidated revenue of ₹392.7 crore, up 51% year-on-year, while profit after tax rose 12% to ₹45.4 crore. The result points to continued growth in the hospital operator's scale, although its profit margin declined to 12% from 16% a year earlier as expenses increased.

What did Yatharth Hospital report for Q1 FY27?

Yatharth Hospital reported a record first quarter for FY27, with consolidated revenue of ₹392.7 crore, EBITDA of ₹91.7 crore and PAT of ₹45.4 crore. Revenue was also shown as ₹397.01 crore under total income in the quarterly financial data, which includes income beyond sales. The company reported earnings per share of ₹4.88, compared with ₹4.36 in Q1 FY26.

The financial performance extended the company's recent quarterly growth trend. Sales rose from ₹258 crore in June 2025 to ₹393 crore in June 2026, while operating profit increased from ₹64 crore to ₹92 crore over the same period. EBITDA rose from ₹73.8 crore to ₹96.0 crore, based on the quarterly data supplied.

PAT increased from ₹42.0 crore in June 2025 to ₹45.4 crore in June 2026. However, the pace of profit growth was below revenue growth. The reported net profit margin declined to 12% from 16% in the comparable previous-year quarter, with higher expenses identified as the reason for the reduction.

What supported Yatharth Hospital's quarterly growth?

The reported growth was supported by operating leverage and utilisation at mature hospitals. Management highlighted a group average revenue per occupied bed, or ARPOB, of ₹34,758. It also said several mature facilities were operating at occupancy levels near or above 70%.

These operating indicators matter because hospital revenue depends on occupied beds, the mix of treatments and the revenue earned per occupied bed. The available disclosures do not provide a hospital-wise break-up of occupancy, revenue or expenses. They nevertheless show that the company linked its Q1 performance to stronger utilisation across established locations.

The quarterly sequence also indicates sustained expansion in the operating base. Sales increased from ₹320 crore in December 2025 to ₹342 crore in March 2026 and ₹393 crore in June 2026. Operating profit moved from ₹74 crore to ₹80 crore and then ₹92 crore across the same three quarters.

How have Yatharth Hospital's quarterly numbers changed over time?

Yatharth Hospital's reported sales and operating profit have risen steadily over the past several quarters. Sales were ₹155 crore in June 2023 and reached ₹393 crore by June 2026, while operating profit increased from ₹41 crore to ₹92 crore during that period.

The five-quarter financial series shows total income rising from ₹267.1 crore in June 2025 to ₹288.9 crore in September 2025, ₹328.3 crore in December 2025, ₹348.7 crore in March 2026 and ₹397.0 crore in June 2026. EBITDA also grew from ₹73.8 crore in June 2025 to ₹96.0 crore in June 2026.

But margins require attention alongside the expansion in revenue. The Q1 earnings summary said higher expenses reduced net profit margin to 12% from 16% a year earlier. This means the company's earnings improved in absolute terms, but a smaller portion of revenue translated into net income than in the prior-year quarter.

When will Yatharth Hospital announce its Q2 FY27 results?

Yatharth Hospital is scheduled to consider and approve its unaudited Q2 FY27 financial results at a board meeting on November 3, 2026. The company had informed BSE of the meeting through an intimation dated October 26, 2026.

The company has also scheduled an earnings conference call for November 4, 2026 at 11:00 AM IST. Management is expected to discuss the unaudited Q2 FY27 results and outlook with analysts and investors during the call. The supplied material does not contain the Q2 FY27 financial figures.

The timing is relevant for investors following the trend seen in the first quarter. The next results will provide updated information on revenue growth, operating expenses, occupancy and profitability after the Q1 margin decline. Until then, the Q1 FY27 report remains the latest disclosed quarterly operating update in the provided information.

What does the result mean for investors and the hospital sector?

For investors, the result shows that Yatharth Hospital continued to deliver strong top-line growth, with Q1 FY27 revenue reported at ₹392.7 crore and EBITDA at ₹91.7 crore. The company also reported that revenue is forecast to grow at an average rate of 27% annually over the next three years, compared with an 18% growth forecast for India's healthcare industry. This is a forecast cited in the source, not a company guidance figure.

The margin movement is equally important. Expenses grew alongside operations, and the reported net margin fell by four percentage points year-on-year. Investors will therefore need to assess future results for the balance between revenue expansion and cost management rather than relying only on sales growth.

The data also provides context for the company's market performance. Over the past three years, earnings per share increased by an average of 15% annually, while the share price increased by 37% annually, according to the supplied information. That comparison indicates the share price rose faster than earnings over that period, though it does not establish how the stock will perform in the future.

Conclusion

Yatharth Hospital's Q1 FY27 result showed a substantial increase in revenue, with consolidated revenue reaching ₹392.7 crore and EBITDA reaching ₹91.7 crore. Higher occupancy at mature hospitals and a group ARPOB of ₹34,758 were cited as operating supports, while the decline in net profit margin to 12% showed the effect of higher expenses.

The next confirmed event is the November 3, 2026 board meeting for unaudited Q2 FY27 results, followed by the November 4 earnings call. Investors will watch for updated revenue, profitability, occupancy and expense data, particularly whether the company can maintain growth while addressing the margin pressure disclosed in Q1.